There were 531 press releases posted in the last 24 hours and 160,092 in the last 365 days.

Global Seasonal Influenza Vaccines Markets 2016/2017-2025/2026

/EIN News/ -- Dublin, Aug. 11, 2017 (GLOBE NEWSWIRE) -- The "Seasonal Influenza Vaccines" report has been added to Research and Markets' offering.

Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types and can be further classified by serotype based on antibody response to the virus.

Seasonal influenza presents significant public health problems for nearly every country, largely because of the cost associated with the treatment or management of the disease, as well as the toll on the workforce. Vaccination against seasonal influenza is the most effective method of preventing influenza infection. However, global vaccination rates remain lower than the levels recommended by the World Health Organization.

Recent events and opinion:

  • Quadrivalent vaccines are seeing rapid uptake and will gradually replace trivalent vaccines in all patient groups in the US and EU markets
  • The broadening of recommendations to include school-aged children will drive EU market growth significantly
  • Adjuvanted vaccines in development have the potential to address unmet needs in infants and the elderly

Key Topics Covered:

Forecast: Seasonal Influenza Vaccines

Executive Summary

  • Market Overview and Trends
  • Key Drivers and Resistors of Conversion to QIVs
  • Market Definition
  • US Market Forecast
  • France Market Forecast
  • Germany Market Forecast
  • Italy Market Forecast
  • Spain Market Forecast
  • UK Market Forecast

Marketed Drugs: Seasonal Influenza Vaccines

  • Executive Summary
  • Product Overview
  • Product profile: FluMist QIV
  • Product profile: Flucelvax QIV
  • Product profile: Fluzone High-Dose

Pipeline: Seasonal Influenza Vaccines

  • Executive Summary
  • Clinical Pipeline Overview
  • Product profile (late stage): Fluad QIV

For more information about this report visit

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Vaccines

Primary Logo